Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction.

Ali Javaheri Ahmed DiabLei ZhaoChenao QianJordana B Cohen Payman ZamaniAnupam KumarZhaoqing WangChristina EbertJoseph MaranvilleErika KvikstadMichael BassoVanessa P M van Empel Arthur Mark RichardsRobert N DoughtyErnst RietzschelKarl KammerhoffJoseph GogainPeter SchaferDietmar A SeiffertDavid A GordonFrancisco Ramírez-Valle Douglas L MannThomas P CappolaJulio Alonso Chirinos

Published in: Circulation. Heart failure (2022)

Proteomic analysis in the TOPCAT trial revealed proteins and pathways altered by spironolactone, including the caspase inhibitor CARD18 and multiple pathways that involved collagens. In addition to effects on fibrosis, our studies suggest potential antiapoptotic effects of spironolactone in heart failure with preserved ejection fraction, a hypothesis that merits further exploration.

Keyphrases

cell death
study protocol
clinical trial
phase iii
single cell
phase ii
induced apoptosis
case control
open label